By Tim Schwab
In September 2010, the FDA appeared primed to approve AquaBounty’s genetically engineered (GE) salmon, the hormone-enhanced fish that, nevertheless, can’t live up to its fast-growth hype. Trumpeting unprecedented transparency, the FDA released to the public hundreds of pages of the agency’s favorable risk assessment, along with an announcement of a days-away public meeting in Rockville, Maryland. The extremely short timeline seemed designed to limit public participation and independent criticisms of the FDA’s scientific work, as few people could drop everything and rush to Maryland.
On the Friday before Christmas 2012, the agency that protects 80 percent of our food supply gave us an encore performance. On a day when few people are at work and many are making plans for extended vacations, the FDA issued its environmental assessment, a 160-page document that basically regurgitates verbatim the agency’s weak 2010 assessment. This moves AquaBounty’s GE salmon within one step of full approval.
The FDA’s risk assessments are noteworthy, not for what they do tell us, but for what they don’t. Instead of scrutinizing the flawed science, limited data, examples of bias and lingering safety concerns that independent scientists have highlighted, the FDA continues to treat its risk assessment as an exercise in churning out the Frankenstein refrain: GE salmon. Safe. Good.